Research attention from clinical trials, public agencies and PubMed
| HCV (n, %) | HBV | NAFLD | ALD | |
|---|---|---|---|---|
| Drugs in development | 61 (82) | 9 (12) | 2 (3) | 2 (3) |
| EASL | 1478 (55) | 663 (25) | 356 (13) | 179.5 (7) |
| AASLD | 2131 (49) | 1401 (32) | 621.5 (14) | 135 (5) |
| PubMed | 15 438 (39) | 10 724 (27) | 5518 (14) | 1728 (4) |
| NIH grants | 738 (48) | 328 (21) | 300 (20) | 47 (3) |
| EU grants | 52.5 (61) | 25.5 (30) | 6 (7) | 0 (0) |
| Clinical trials | 407 (32) | 461 (36) | 66 (5) | 235 (18) |
| Mean research attention | 47% | 31% | 17% | 5% |
Percentages in parentheses calculated from a combination of HCV, HBV, NAFLD and ALD.
AASLD, American Association for the Study of the Liver; ALD, alcoholic liver disease; EASL, European Association for the Study of Liver Diseases; EU, European Union; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; NIH, National Institutes of Health.